ArticleEClinicalMedicine2025
The effect of tranexamic acid on blood coagulation in primary total hip arthroplasty using rotational thromboelastometry: a randomized controlled trial.
Article in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Effect of Tranexamic Acid on Blood Coagulation in Total Hip Arthroplasty Surgery Based on Rotational Thromboelastometry (ROTEM®).
A Prospective Randomized Controlled Trial Comparing Plasma Concentrations of Intraosseous and Intravenous Tranexamic Acid in Patients Undergoing Joint Arthroplasty
Who cites it
2 citing papers in PubMed.
- Intravenous Tranexamic Acid Reduces Perioperative Blood Loss in Reduction Mammoplasty With Immediate Implant-Based Reconstruction: A Randomized, Triple-Blinded, Placebo-Controlled Trial.Aesthetic surgery journal · 2026Trial
- Precision-guided tranexamic acid administration in total hip arthroplasty: integrating viscoelastic testing and patient risk stratification into perioperative hemostasis - a narrative review.Annals of medicine and surgery (2012) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tranexamic acid (TXA), is commonly administered prophylactically to reduce blood loss in patients undergoing total hip arthroplasty (THA). However, its effect has never been studied. We hypothesized that no difference exists in the degree of fibrinolysis and blood loss between patients receiving prophylactic TXA and placebo. Methods: This double-blinded randomized-controlled trial included 50 patients undergoing primary THA in 2021-2023. Clinicaltrials.gov (NCT03897621). Rotational-thromboelastometry (ROTEM) were performed to test blood coagulability using non citrated whole blood (NATEM) and blood treated with TXA (T-APTEM). The intervention group received TXA intravenously. The placebo group received 0.9% sodium chloride solution. The primary outcome measure was to quantitate the degree of fibrinolysis measured by maximum lysis (ML) demonstrated by ROTEM variables. Fibrinolysis was defined as ML (maximum lysis) > 15% within 1 h of testing. Findings: Blood coagulability tested by ROTEM was within the normal range in all patients, and no difference was found between the TXA group and placebo group.NATEM and T-APTEM variables were similar in both groups and no patient developed fibrinolysis during the entire perioperative phases. At baseline, T-APTEM, compared with NATEM, showed shorter CT (746 ± 265 vs. 991 ± 237 p < 0.05) and greater ML (1.9 ± 2.2 vs. 0.8 ± 1, p < 0.05), suggesting some degree of acceleration of coagulation. Postoperatively, blood coagulability showed a tendency of acceleration with shorter CT (689 ± 188 vs. 828 ± 163, p < 0.05) and CFT (258 ± 101 vs. 293 ± 87 p < 0.05) and increased A10 (41 ± 9 vs. 38 ± 8, p < 0.05). Clinical outcomes, including blood loss, hematologic variables, and coagulation profile were similar between the two groups. Interpretation: Normal range of blood coagulability in all patients, no significant differences between NATEM and T-APTEM variables, and similar clinical outcome between the two groups suggest that there is no definitive medical indication for TXA administration in patients undergoing THA without a preexisting fibrinolytic condition. Monitoring blood coagulability using ROTEM may be useful in guiding selective administration of TXA in high-risk patients. Funding: Department of Anesthesiology funding, Thomas Jefferson University Hospital. Support was provided solely from institutional and/or departmental sources.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.